Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
Mar 04  •  04:00PM ET
1.73
Dollar change
+0.05
Percentage change
2.98
%
Today, 8:10 AMInovio, Akeso to test INO-5412 with cadonilimab in Phase 2 INSIGhT glioblastoma trial
Index- P/E- EPS (ttm)-2.58 Insider Own0.42% Shs Outstand68.70M Perf Week-6.49%
Market Cap118.86M Forward P/E- EPS next Y-1.39 Insider Trans0.00% Shs Float68.42M Perf Month1.76%
Enterprise Value78.08M PEG- EPS next Q-0.36 Inst Own48.08% Short Float16.69% Perf Quarter-9.90%
Income-108.09M P/S660.31 EPS this Y42.53% Inst Trans22.08% Short Ratio7.95 Perf Half Y-32.68%
Sales0.18M P/B- EPS next Y38.77% ROA-122.52% Short Interest11.42M Perf YTD-0.57%
Book/sh-0.14 P/C2.34 EPS next 5Y43.83% ROE-328.45% 52W High2.98 -41.92% Perf Year-11.28%
Cash/sh0.74 P/FCF- EPS past 3/5Y39.06% 22.92% ROIC- 52W Low1.30 33.08% Perf 3Y-89.08%
Dividend Est.- EV/EBITDA- Sales past 3/5Y-50.31% -44.44% Gross Margin-1551.12% Volatility4.18% 6.51% Perf 5Y-98.42%
Dividend TTM- EV/Sales433.75 EPS Y/Y TTM42.36% Oper. Margin-49202.88% ATR (14)0.11 Perf 10Y-97.94%
Dividend Ex-Date- Quick Ratio0.79 Sales Y/Y TTM-10.36% Profit Margin-59281.69% RSI (14)50.90 Recom1.80
Dividend Gr. 3/5Y- - Current Ratio0.79 EPS Q/Q2.48% SMA201.41% Beta1.76 Target Price6.76
Payout- Debt/Eq- Sales Q/Q- SMA501.22% Rel Volume0.48 Prev Close1.68
Employees134 LT Debt/Eq- EarningsNov 10 AMC SMA200-12.34% Avg Volume1.44M Price1.73
IPODec 08, 1998 Option/ShortYes / Yes EPS/Sales Surpr.-106.31% - Trades Volume683,822 Change2.98%
Date Action Analyst Rating Change Price Target Change
Jul-09-25Initiated Piper Sandler Overweight $5
May-14-24Initiated Stephens Overweight $20
Jan-25-24Upgrade Oppenheimer Perform → Outperform $4
Nov-09-22Downgrade Maxim Group Buy → Hold
Nov-01-22Downgrade BofA Securities Neutral → Underperform $2
Jul-19-22Resumed RBC Capital Mkts Sector Perform $5 → $4
May-11-22Downgrade Oppenheimer Outperform → Perform
Jan-21-22Upgrade BofA Securities Underperform → Neutral $8 → $10
Dec-29-21Resumed Jefferies Hold $8 → $6
Sep-10-21Downgrade BofA Securities Neutral → Underperform $9 → $8
Today 09:00AM
08:05AM
Feb-26-26 09:16AM
Feb-25-26 09:00AM
Feb-20-26 04:27AM
08:05AM Loading…
Feb-12-26 08:05AM
07:30AM
Dec-30-25 08:10AM
Dec-29-25 08:05AM
Dec-19-25 04:05PM
Nov-18-25 08:05AM
Nov-14-25 12:00PM
Nov-11-25 08:40AM
12:00AM
Nov-10-25 06:09PM
04:17PM Loading…
04:17PM
04:05PM
Nov-03-25 08:05AM
Oct-31-25 04:53PM
Oct-27-25 08:05AM
Oct-23-25 04:05PM
Oct-21-25 08:05AM
Oct-02-25 08:05AM
Sep-25-25 08:05AM
Aug-28-25 10:00AM
Aug-26-25 08:05AM
Aug-25-25 11:04AM
08:05AM
Aug-14-25 12:22PM
Aug-13-25 03:11AM
04:20PM Loading…
Aug-12-25 04:20PM
04:05PM
Aug-11-25 06:55PM
09:10AM
08:05AM
Aug-07-25 10:00AM
Aug-05-25 10:00AM
Aug-04-25 04:05PM
Jul-07-25 04:05PM
Jul-03-25 07:30AM
Jul-02-25 04:16PM
Jul-01-25 07:00AM
May-14-25 12:43PM
03:15AM
May-13-25 05:40PM
04:39PM
04:05PM
Apr-30-25 08:05AM
Apr-29-25 08:05AM
Apr-21-25 07:40AM
Apr-09-25 12:00PM
08:05AM
Apr-01-25 09:35AM
Mar-19-25 03:02AM
Mar-18-25 10:15PM
04:05PM
Mar-13-25 06:15PM
Mar-12-25 12:55PM
Feb-12-25 09:55AM
08:00AM
Feb-10-25 08:05AM
Jan-29-25 04:14PM
Jan-09-25 08:04AM
Dec-13-24 07:00AM
Dec-12-24 04:01PM
Dec-03-24 08:00AM
Nov-29-24 04:02PM
Nov-15-24 02:15AM
02:08AM
Nov-14-24 09:15PM
04:27PM
04:05PM
Nov-13-24 08:00AM
Nov-06-24 04:05PM
08:00AM
Oct-21-24 08:00AM
Oct-09-24 05:38AM
Oct-02-24 04:15PM
Oct-01-24 08:00AM
Sep-17-24 04:30PM
Sep-04-24 08:30AM
Aug-09-24 02:30AM
Aug-08-24 04:40PM
04:05PM
Aug-01-24 04:05PM
Jul-25-24 04:05PM
08:00AM
Jul-12-24 10:09AM
09:28AM
Jul-11-24 08:00AM
Jul-02-24 04:05PM
Jul-01-24 04:00PM
08:00AM
Jun-04-24 08:00AM
May-31-24 04:48PM
May-22-24 09:45AM
May-14-24 08:21AM
07:55AM
03:02AM
May-13-24 09:45PM
Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.